Proinsulin, Intact/Insulin Ratio
0070256
Ordering Recommendation
Aids in the detection of insulinoma. Do not use to diagnose diabetes mellitus.
Mnemonic
PRO INS
Methodology
Quantitative Chemiluminescent Immunoassay/Quantitative Chemiluminescent Immunoassay
Performed
Refer to individual components
Reported
1-6 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
Patient must be fasting for 12-15 hours prior to collection.  
Collect
Serum separator tube. Also acceptable: Lavender (EDTA) or pink (K2EDTA).  
Specimen Preparation
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube and freeze immediately. (Min: 0.8 mL)  
Storage/Transport Temperature
Frozen.  
Unacceptable Conditions
Heparinized plasma. Vitreous or I.V. fluids. Hemolyzed specimens.  
Remarks
  
Stability
After separation from cells: Ambient: Unacceptable; Refrigerated: 48 hours; Frozen: 2 months (avoid repeated freeze/thaw cycles)  
Reference Interval
 
 
Available Separately Component Reference Interval
Yes (0070063) Insulin, Fasting 3-​19 µIU/mL
Yes (0070112) Proinsulin, Intact 0-​17 years: Not established
Effective May 19th, 2014
18 years and older: Less than or equal to 8.0 pmol/L
No Proinsulin, Intact/Insulin Ratio Calculation Proinsulin, Intact/Insulin Ratio as Percent:
0-​17 years: Not established
18 years and older: 0.8-​21.7 percent
Interpretive Data
Insulin, Fasting: This test reacts on a nearly equimolar basis with the analogs insulin aspart, insulin glargine, and insulin lispro. Insulin detemir exhibits approximately 50 percent cross-reactivity. Test reactivity with insulin glulisine is negligible (less than 3 percent). To convert to pmol/L, multiply µIU/mL by 6.0.

Proinsulin, Intact: Fasting intact proinsulin values above the reference interval indicate a possible insulin secreting pancreatic tumor (insulinoma) in patients with hypoglycemia. Fasting intact proinsulin values range from 3 to 50 pmol/L in patients with untreated type 2 diabetes.

See Compliance Statement D: www.aruplab.com/CS
Statement D: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
 
Note
 
CPT Code(s)
84206; 83525
Components
Component Test Code*Component Chart Name
0070063Insulin, Fasting
0070112Proinsulin, Intact
0070257Proinsulin, Intact/Insulin Ratio Calc
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases